Immune Profiling for Cancer Immunotherapy Response

Launched by DARTMOUTH-HITCHCOCK MEDICAL CENTER · Oct 30, 2023

Keywords

ClinConnect Summary

This clinical trial, called "Immune Profiling for Cancer Immunotherapy Response," is studying how certain immune markers in the body can help predict how well cancer treatments work. Specifically, researchers want to look at patients who are receiving FDA-approved immunotherapy treatments, like pembrolizumab, nivolumab, or ipilimumab, to see how changes in immune profiles before and during treatment can give insights into treatment effectiveness. This study includes patients with various types of cancer, including solid tumors and blood cancers.

To join this trial, participants must be cancer patients who are currently receiving or will receive one of the specified immunotherapies. It doesn’t matter if they have had other treatments before. Unfortunately, pregnant women, prisoners, and those unable to make their own medical decisions cannot participate. Those involved in the trial can expect to provide samples for testing, which will help researchers learn more about how the immune system responds to treatment. This information could potentially lead to better personalized cancer therapies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
• • Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
• Exclusion Criteria:
• • Pregnant women/fetuses/neonates
• • Prisoners
• • Decision-impaired individuals